TITLE

Tumour Heterogeneity: The Key Advantages of Single-Cell Analysis

AUTHOR(S)
Tellez-Gabriel, Marta; Ory, Benjamin; Lamoureux, Francois; Heymann, Marie-Francoise; Heymann, Dominique
PUB. DATE
December 2016
SOURCE
International Journal of Molecular Sciences;Dec2016, Vol. 17 Issue 12, p2142
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Tumour heterogeneity refers to the fact that different tumour cells can show distinct morphological and phenotypic profiles, including cellular morphology, gene expression, metabolism, motility, proliferation and metastatic potential. This phenomenon occurs both between tumours (inter-tumour heterogeneity) and within tumours (intra-tumour heterogeneity), and it is caused by genetic and non-genetic factors. The heterogeneity of cancer cells introduces significant challenges in using molecular prognostic markers as well as for classifying patients that might benefit from specific therapies. Thus, research efforts for characterizing heterogeneity would be useful for a better understanding of the causes and progression of disease. It has been suggested that the study of heterogeneity within Circulating Tumour Cells (CTCs) could also reflect the full spectrum of mutations of the disease more accurately than a single biopsy of a primary or metastatic tumour. In previous years, many high throughput methodologies have raised for the study of heterogeneity at different levels (i.e., RNA, DNA, protein and epigenetic events). The aim of the current review is to stress clinical implications of tumour heterogeneity, as well as current available methodologies for their study, paying specific attention to those able to assess heterogeneity at the single cell level.
ACCESSION #
120516966

 

Related Articles

  • Expression of RAGE and HMGB1 in Thymic Epithelial Tumors, Thymic Hyperplasia and Regular Thymic Morphology. Moser, Bernhard; Janik, Stefan; Schiefer, Ana-Iris; Müllauer, Leonhard; Bekos, Christine; Scharrer, Anke; Mildner, Michael; Rényi-Vámos, Ferenc; Klepetko, Walter; Ankersmit, Hendrik Jan // PLoS ONE;Apr2014, Vol. 9 Issue 4, p1 

    Recently, a role of the receptor for advanced glycation endproducts (RAGE) in myasthenia gravis was described. RAGE and its ligand high mobility group box 1 (HMGB1) play key roles in autoimmunity and cancer. To test whether these molecules are involved in patients with thymic abnormalities we...

  • Lymphoma Researchers In Search of Molecular Targets. Friedrich, M. J. // JNCI: Journal of the National Cancer Institute;Jul2010, Vol. 102 Issue 14, p1000 

    The article examines medical approaches to treat aggressive non-Hodgkin lymphoma. It discusses the development of pixantrone, an anthracenedione which may be an improved version of anthracycline doxorubin, one of the main drugs used to treat aggressive lymphomas. It also discusses the use of...

  • The expression of BTG1 is downregulated in nasopharyngeal carcinoma and possibly associated with tumour metastasis. Sun, G.; Wang, Y.; Cheng, Y.; Hu, W. // Molecular Biology Reports;Sep2014, Vol. 41 Issue 9, p5979 

    To determine the expression and function of B cell translocation gene 1 (BTG1) in nasopharyngeal carcinoma. Nasopharyngeal samples were taken from cancer lesions ( n = 75) and adjacent normal tissue ( n = 33) in nasopharyngeal cancer patients immediately after endoscopic biopsy. BTG1 expression...

  • Differential expression of Mediator complex subunit MED15 in testicular germ cell tumors. Klümper, Niklas; Syring, Isabella; Offermann, Anne; Shaikhibrahim, Zaki; Vogel, Wenzel; Müller, Stefan C.; Ellinger, Jörg; Strauß, Arne; Joachim Radzun, Heinz; Ströbel, Philipp; Brägelmann, Johannes; Perner, Sven; Bremmer, Felix // Diagnostic Pathology;9/17/2015, Vol. 10 Issue 1, p1 

    Background: Testicular germ cell tumors (TGCT) are the most common cancer entities in young men with increasing incidence observed in the last decades. For therapeutic management it is important, that TGCT are divided into several histological subtypes. MED15 is part of the multiprotein Mediator...

  • Molecular heterogeneity of diffuse large B-cell lymphoma. Gascoyne, Randy D. // Hematology Journal;2004 Supplement 3, Vol. 5, pS144 

    Studies the molecular genetic heterogeneity of diffuse large B-cell lymphoma. Disease initiative events;Loss of critical tumor suppressor genes; Gene copy number alterations; Gene expression profiles.

  • Aberrant expression of CD8 in B-cell non-Hodgkin lymphoma: a multicenter study of 951 bone marrow samples with lymphomatous infiltration. Giovanni Carulli; Alessandra Stacchini; Alessandra Marini; Maria Matilde Ciriello; Alessandra Zucca; Elisa Cannizzo; Sabrina Aliberti; Anna Demurtas; Domenico Novero; Lara Calcagno; Tiziana Callegari; Mario Petrini // American Journal of Clinical Pathology;Aug2009, Vol. 132 Issue 2, p186 

    T-cell antigen expression can be observed in B-cell non-Hodgkin lymphoma (B-NHL). Although CD5 is expressed in B-cell chronic lymphocytic leukemia (B-CLL) and mantle cell lymphoma, the presence of other T-cell antigens is less common. This article reports a retrospective multicenter analysis in...

  • 2-faced leukemia?  // Biomedical Market Newsletter;12/14/2011, Vol. 21, p1 

    The article focuses on the prognosis of T cell acute lymphoblastic leukemia (T-ALL) and acute myeloid leukemia (AML). Only 50% of adult T-ALL patients can be cured, according to a study by Columbia University Institute for Cancer Genetics. They examined the genes expressed in tumors from T-ALL...

  • Expression Profiling of Transcription Factors in B- or T-Acute Lymphoblastic Leukemia/Lymphoma and Burkitt Lymphoma: Usefulness of PAX5 Immunostaining as Pan–Pre-B-Cell Marker. Michel R. Nasr // American Journal of Clinical Pathology;Jan2010, Vol. 133 Issue 1, p41 

    The optimal use of transcription factors to determine B-lineage specificity in B-acute lymphoblastic leukemia/lymphoma (B-ALL) has not been fully investigated. We undertook an extensive immunohistochemical study of a panel of B-cell transcription factors in B- and T-ALL and Burkitt lymphoma to...

  • Are We Ready To Stratify Treatment for Diffuse Large B-Cell Lymphoma Using Molecular Hallmarks? Barton, Sarah; Hawkes, Eliza A.; Wotherspoon, Andrew; Cunningham, David // Oncologist;Dec2012, Vol. 17 Issue 12, p1562 

    The division of the heterogeneous entity of diffuse large Bcell lymphoma (DLBCL) into the ontogenic phenotypes of germinal center B-cell-like (GCB) and activated B-cell-like (ABC) is optimally determined by gene expression profiling (GEP), although simpler immunohistochemistry (IHC) algorithms...

  • Expression of CD26 and CXCR4 in prostate carcinoma and its relationship with clinical parameters. Zhong Lu; Li Qi; Xue Jun Bo; Guo Dong Liu; Jun Ming Wang; Guixin Li // Journal of Research in Medical Sciences;Aug2013, Vol. 18 Issue 8, p647 

    Background: Prostate cancer is one of the most common cancer types both in western and eastern countries, involving mostly elder men. The mechanisms underlying the prostate cancer development remain unclear. Prostate-specific antigen (PSA) is the only well accepted marker for prostate cancer...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics